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Sarcopenia, as defined by the European 
Working Group on Sarcopenia (EWGSOP) in 
Older People is “a progressive and generalized 
skeletal muscle disorder that is associated 
with increased likelihood of adverse outcomes 
including falls, fractures, physical disability, 
and mortality”.1 The first EWGSOP and Asian 
Working Group for Sarcopenia used muscle mass 
to define sarcopenia, which is diagnosed by using 
Dual-energy X-Ray absorptiometry (DXA). 
However, the cut-off from several countries in 
Asian showed different cut-off value for different 
age groups and BMI. In addition, not all hospitals 
and countries can afford DXA to be used as daily 
diagnostic routine for sarcopenia.2
In 2018, EWGSOP made a revision regarding 
sarcopenia, as well as the diagnostic test and cut-
off value (EWGSOP2). EWGSOP2 recommends 
using self-questionnaire, known as SARC-F as 
sarcopenia screening, especially in community-
dwelling elderly. SARC-F consisted of 5 
questions regarding patient’s perception of his or 
her limitations in strength, walking ability, rising 
from a chair, stair climbing and experiences with 
falls. This is more feasible to be done in countries 
without advanced muscle mass measurement 
tools. Several parameters in sarcopenia are 
muscle strength, muscle quantity, and physical 
performance. In muscle strength, measuring grip 
strength can be done as predictor for patients’ 
outcomes, such as hospitalization and quality 
of life. For muscle quantity, the gold standards 
are Magnetic resonance imaging (MRI) and 
computed tomography (CT). However, since 
both are expensive, and the cut-off points have 
not been defined yet, DXA and Bioelectrical 
impedance analysis (BIA) can be a substitute. 
Current evidence showed that DXA still does 
not give consistent results and not yet portable 
for the use in the community. On the other hand, 
BIA measure muscle mass using the whole-
body electrical conductivity and less expensive 
than the other tools, thus can be used in the 
community setting. However, there is no specific 
cut-off for BIA especially in elderly. For physical 
performance, several tests can be done, such as 
gait speed and Timed-Up and Go test (TUG).
Study done by Setiati, et al showed that 
SARC-F combined with calf and/or thigh 
circumference measurement can be used 
in community and hospital setting to make 
diagnosis of sarcopenia as it has high specificity 
value. Both calf and thigh circumference 
measurement can be widely used in community 
elderly as it does not use expensive equipment 
and it complements to establish sarcopenia 
diagnosis. This research is a novel study as past 
studies did not combine both calf and/or thigh 
circumference with SARC-F. Past studies used 
only calf or thigh circumference to complement 
SARC-F to establish sarcopenia.
Furthermore, Laksmi, et al did a research 
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to find the cut-off value of BIA in comparison 
to DXA and found out that the sensitivity and 
specificity for male was 70.6% and 82.8% (BIA 
<6.9 kg/m2) and for female was 85.7% and 97% 
(BIA <5 kg/m2). BIA is not as expensive as 
DXA and it can be used in community setting 
thus it make clinicians easier to measure muscle 
quantity as part of the sarcopenia. The cut-off 
value in the study slightly below the normal cut-
off value for BIA based on EWGSOP, which was 
<7 kg/m2 for male and <5.7 kg/m2 for female. 
BIA, even though not all hospitals have the tool, 
it is more feasible to be find and used compared 
to DXA, thus this is a promising evidence about 
sarcopenia diagnosis research.
Further research in different settings are 
still required regarding the external validation 
for both studies mentioned above to ensure the 
applicability of the tools in all levels of health 
care services, as currently there are no external 
validations for those tools.
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